226 related articles for article (PubMed ID: 9973200)
41. TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells.
Kamesaki H; Nishizawa K; Michaud GY; Cossman J; Kiyono T
J Immunol; 1998 Jan; 160(2):770-7. PubMed ID: 9551912
[TBL] [Abstract][Full Text] [Related]
42. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Shapiro GI; Park JE; Edwards CD; Mao L; Merlo A; Sidransky D; Ewen ME; Rollins BJ
Cancer Res; 1995 Dec; 55(24):6200-9. PubMed ID: 8521414
[TBL] [Abstract][Full Text] [Related]
43. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
44. Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer.
Blais A; Labrie Y; Pouliot F; Lachance Y; Labrie C
Biochem Biophys Res Commun; 1998 Jun; 247(1):146-53. PubMed ID: 9636670
[TBL] [Abstract][Full Text] [Related]
45. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
Kulkarni MS; Daggett JL; Bender TP; Kuehl WM; Bergsagel PL; Williams ME
Leukemia; 2002 Jan; 16(1):127-34. PubMed ID: 11840272
[TBL] [Abstract][Full Text] [Related]
46. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
Sandhu C; Peehl DM; Slingerland J
Cancer Res; 2000 May; 60(10):2616-22. PubMed ID: 10825132
[TBL] [Abstract][Full Text] [Related]
47. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Li J; Joo SH; Tsai MD
Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
[TBL] [Abstract][Full Text] [Related]
48. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
49. Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma.
Morishita A; Masaki T; Yoshiji H; Nakai S; Ogi T; Miyauchi Y; Yoshida S; Funaki T; Uchida N; Kita Y; Funakoshi F; Usuki H; Okada S; Izuishi K; Watanabe S; Kurokohchi K; Kuriyama S
Hepatology; 2004 Sep; 40(3):677-86. PubMed ID: 15349907
[TBL] [Abstract][Full Text] [Related]
50. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.
Sotillo R; Renner O; Dubus P; Ruiz-Cabello J; Martín-Caballero J; Barbacid M; Carnero A; Malumbres M
Cancer Res; 2005 May; 65(9):3846-52. PubMed ID: 15867383
[TBL] [Abstract][Full Text] [Related]
51. Genetic evidence for functional dependency of p18Ink4c on Cdk4.
Pei XH; Bai F; Tsutsui T; Kiyokawa H; Xiong Y
Mol Cell Biol; 2004 Aug; 24(15):6653-64. PubMed ID: 15254233
[TBL] [Abstract][Full Text] [Related]
52. Direct binding of the N-terminus of HTLV-1 tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity.
Li J; Li H; Tsai MD
Biochemistry; 2003 Jun; 42(22):6921-8. PubMed ID: 12779347
[TBL] [Abstract][Full Text] [Related]
53. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
Villacañas O; Pérez JJ; Rubio-Martínez J
J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
[TBL] [Abstract][Full Text] [Related]
54. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
55. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.
Hannon GJ; Beach D
Nature; 1994 Sep; 371(6494):257-61. PubMed ID: 8078588
[TBL] [Abstract][Full Text] [Related]
56. Structure of the cyclin-dependent kinase inhibitor p19Ink4d.
Luh FY; Archer SJ; Domaille PJ; Smith BO; Owen D; Brotherton DH; Raine AR; Xu X; Brizuela L; Brenner SL; Laue ED
Nature; 1997 Oct; 389(6654):999-1003. PubMed ID: 9353127
[TBL] [Abstract][Full Text] [Related]
57. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4.
Chan FK; Zhang J; Cheng L; Shapiro DN; Winoto A
Mol Cell Biol; 1995 May; 15(5):2682-8. PubMed ID: 7739548
[TBL] [Abstract][Full Text] [Related]
58. Analysis of p16INK4a and its interaction with CDK4.
Yang R; Serrano M; Slater J; Leung E; Koeffler HP
Biochem Biophys Res Commun; 1996 Jan; 218(1):254-9. PubMed ID: 8573142
[TBL] [Abstract][Full Text] [Related]
59. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
[TBL] [Abstract][Full Text] [Related]
60. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
Reymond A; Brent R
Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
